A PE investment firm headquartered in Singapore makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.2m to $10m.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and supplier companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has flexible investment criteria but a cross border strategy  is very important as the firm is less interested in companies whose business focus is restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fund backed by a medical foundation makes investments in start-ups that fundamentally improve patient care in the area of orthopedic, spine & trauma surgery. While the firm will invest globally, the current focus is on companies located in North America, Europe and Israel. The firm prefers to participate in Series A rounds, investing between $1-2.5M with the potential to provide additional capital in later rounds.

The firm looks to fund companies with disruptive technologies in medical devices, diagnostics, and healthcare IT/digital health in the trauma and orthopedic surgery space. This includes technologies for before, during or after surgery, such as imaging, surgical tools, implantable devices and clinical data management. However, the firm is not currently looking to fund any regenerative medicine or tissue engineering applications within this space. If a medical device or diagnostic, companies should have a working prototype and preclinical data, while healthcare IT/digital health companies should have a running MVP as well as the ability to show market traction.

The firm invests in teams and companies that solve fundamental problems. The firm is looking for a clear market understanding and strong USP.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm headquartered in Tokyo, Japan with additional offices worldwide is currently making new investments from a 2016 fund. The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US, Israel and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm  is currently focused on private companies in the US, Israel and Japan. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund founded in 2016 and based in Australia looks to invest in early-stage companies (pre-seed to series A stages) in therapeutics, medical devices, diagnostics or digital healthcare. The firm is looking for companies located in the Australia/New Zealand area as well as companies from the US with connections to Australia. The firm is especially interested in any company looking to finance and facilitate clinical trials in Australia, due to the firm’s experience and connections in this area and the streamlined Australian clinical trial ecosystem compared to EU and US clinical trial procedures. The firm will invest between $50,000-$150,000.

The firm is interested in companies developing technologies in therapeutics, medical devices, diagnostics or digital healthcare. The firm looks for projects that are in a pre-clinical phase, but both need to have some animal or other proof of principle data as a minimum before the firm will consider investing.

The firm has no management team requirements, but is prepared to actively collaborate with researchers to assist in the development and execution of commercialization strategy. The firm will typically seek to appoint one of its executive team or affiliated experts to the board of directors, to assist the project in its development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund backed by a family-office makes seed and early-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million of total exposure in any single opportunity. The firm is open to opportunities worldwide but has a preference for domestic investment; the fund currently has portfolio companies mostly in North America, Europe, and Oceania.

The firm’s Life Sciences portfolio comprises ~30% of the total fund commitments, and is divided into two core categories. The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a tablet-enabled benchtop microscope, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches rather than traditional. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, The firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic investment firm created by a large pharmaceutical company makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.

The firm invests in therapeutics, and in this sector the firm is interested in both early and late stage assets. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout the USA is investing out of a new fund just raised in early 2019. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. The firm typically makes initial investments of $5-7m, with the potential for total investments of $15m or more. The fund makes growth investments in commercial-stage technologies, and only invests in companies headquartered in North America.

The firm invests in medical devices, diagnostics, digital health, tech-enabled services and consumer healthcare; the fund does not invest in biotech, pharmaceuticals, R&D service providers or industry tools. The firm does not invest in companies that face regulatory risk; investments are made in companies with products that have already received regulatory approval or which do not require regulatory approval. The firm only invests in companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help accelerate the adoption.

The firm prefers to invest in management teams that have prior experience of working in a relevant emerging company environment, and which have significant experience in the sector their company is working in. The fund prefers to work with privately-held companies but the investment team also has past experience of PIPEs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.